Unequivocal Identification of Aspartic Acid and isoAspartic Acid by MALDI-TOF/TOF: From Peptide Standards to a Therapeutic Antibody
- 3 January 2021
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of the American Society for Mass Spectrometry
- Vol. 32 (8), 1901-1909
- https://doi.org/10.1021/jasms.0c00370
Abstract
Aspartic acid (Asp) to isoaspartic acid (isoAsp) isomerization in therapeutic monoclonal antibodies (mAbs) and other biotherapeutics is a critical quality attribute (CQA) that requires careful control and monitoring during the drug discovery and production processes. The unwanted formation of isoAsp within biotherapeutics and resultant structural changes in the peptide backbone may negatively impact the efficacy, potency, and safety of the molecule or become immunogenic, especially if the isomerization occurs within the mAb complementarity determining region (CDR). Herein we describe a MALDI-TOF/TOF mass spectrometry method that affords unequivocal identification of the presence and the exact position of the isoAsp residue(s) in peptide standards ranging in size from a tripeptide to a docosapeptide (22 residues). In general, the peptide bond immediately N-terminal to the isoAsp residue is more susceptible to MALDI-TOF/TOF fragmentation than its unmodified counterpart. In some of the peptides evaluated in this study, fragmentation of the peptide bond C-terminal to the isoAsp residue (the aspartate effect) is also enhanced when compared to the control. Relative quantification by MALDI-TOF/TOF of this chemical modification is dependent upon a successful reversed-phase HPLC (rpHPLC) separation of the control and modified peptides. This method has also been validated on a therapeutic mAb that contains a well-documented isoAsp residue in the heavy chain CDR3 after forced degradation. Moreover, we also demonstrate that higher energy C-trap dissociation of only the singly charged species, and not the multiply charged form, of the isoAsp containing peptide, separated by rpHPLC, results in LC–MS/MS fragmentation that is highly consistent to that of MALDI-TOF/TOF.Keywords
Funding Information
- Foundation for the National Institutes of Health (R01GM103479, S10RR025600)
- UCLA Molecular Instrumentation Center
This publication has 71 references indexed in Scilit:
- The regulation, functions and clinical relevance of arginine methylationNature Reviews Molecular Cell Biology, 2019
- Enzymatic Logic of Ubiquitin Chain AssemblyFrontiers in Physiology, 2019
- Protein O-fucosylation: structure and functionCurrent Opinion in Structural Biology, 2019
- Critical observations that shaped our understanding of the function(s) of intracellular glycosylation (O‐GlcNAc)FEBS Letters, 2018
- Biosimilarity under stress: A forced degradation study of Remicade® and Remsima™mAbs, 2017
- Vertebrate protein glycosylation: diversity, synthesis and functionNature Reviews Molecular Cell Biology, 2012
- Cell signaling, the essential role of O-GlcNAc!Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2006
- Protein Posttranslational Modifications: The Chemistry of Proteome DiversificationsAngewandte Chemie, 2005
- Protein phosphorylation in signaling – 50 years and countingTrends in Biochemical Sciences, 2005
- Non-enzymic post-translational modification of proteins in aging. A reviewMechanisms of Ageing and Development, 1989